printemailclick to share buttonfacebooktwitterlinkedin
Molecular Oncology

The explosion of information about human genetics and its role in cancer has had a profound impact on the testing and treatment of cancer.

Molecular oncology is the study of the molecular mechanisms of cancer. This is an area of exciting growth and opportunity.

Molecular oncology promises to revolutionize diagnosis and treatment

Key molecular oncology issues fit into two broad categories:

  • The use of genetic tests to predict the risk of cancer and to counsel patients
  • The use of knowledge of the molecular makeup of various cancers for diagnostic and prognostic purposes, and to predict responses to specific treatments

Molecular Oncology Advisory Committee

In 2008, we established the Molecular Oncology Task Force to provide advice on how best to deliver standardized, high-quality molecular oncology and oncology genetic counselling in Ontario.

Recommendations from the Task Force led to the formation of the Molecular Oncology Advisory Committee. Although the scope of this project is limited to oncology, the lessons will have the potential to be generalized to non-cancer molecular genetics and genetic counselling services.

Recommendation Reports

  • The Prognostic Value of the DNMT3A Biomarker in Cytogenetically Normal Patients with Acute Myeloid Leukemia
    Recommendation Report MOAC 1: November 2013
    Status: CURRENT
  • Comparison of Oncotype DX with Multi-gene Profiling Assays, (e.g., MammaPrint, PAM50) and Other Tests (e.g., Adjuvant! Online, Ki-67 and IHC4) in Early-stage Breast Cancer
    Recommendation Report MOAC 2: November 2013
    Status: CURRENT
  • Summary Statement: 2013 ASCO/CAP HER2 Guidelines: Building a Consensus for Ontario

Next Generation Sequencing Current State Assessment 

NGS is a high-throughput technology used to sequence genomes. It will allow fast and reliable sequencing of the complete gene, which will become increasingly important as more genetic determinants of cancer are discovered. 

Next generation sequencing (NGS) will have several impacts on:

  • How testing is organized and decisions about what to test
  • Costing and reimbursement models (eg., individual tests vs. panels)
  • Quality
  • Informatics issues such as storage, interpretation, utilization over the long term

It will also have implications for system planning and alignment with Ministry of Health and Long-Term Care activities.

Last modified: Tue, Jun 20, 2017
cancer care ontario | action cancer ontario   620 University Avenue Toronto Ontario, Canada M5G 2L7   Phone: 416.971.9800 Fax: 416.971.6888

Please help improve the quality of our website by answering 10 brief questions in our online survey. Would you like to participate?